June 2018 Br J Cardiol 2018;25:77–80 doi:10.5837/bjc.2018.017
Haqeel A Jamil, Noman Ali, Mohammad Waleed, Yvonne Blackburn, Caroline Moyles, Christopher Morley
Introduction Essential or primary hypertension (HTN), defined as an office blood pressure (BP) ≥140/90 mmHg with no identifiable cause, is a well-documented risk factor for cardiovascular disease, and the most common cardiovascular condition to be seen in primary care.1 It also represents the strongest single modifiable risk factor with regards to future morbidity and mortality.2,3 As such, current guidelines advocate pharmacological treatment if lifestyle measures are insufficient. The National Institute for Health and Care Excellence (NICE) clinical guideline for the treatment of HTN recommends step 1 treatment with an angiotensin-convert
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits